// Auto-generated - do not edit
export const substanceName = "Bromantane";
export const sources = [{"id":"isomerdesign","fileName":"ISOMERDESIGN - Bromantane.md","displayName":"Isomer Design","size":692},{"id":"protestkit","fileName":"PROTESTKIT - Bromantane.json","displayName":"Protest Kit","size":2645},{"id":"psychonautwiki","fileName":"PSYCHONAUTWIKI - Bromantane.md","displayName":"PsychonautWiki","size":19589},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - Bromantane.md","displayName":"TripSit Factsheets","size":384},{"id":"wikipedia","fileName":"WIKIPEDIA - Bromantane.md","displayName":"Wikipedia","size":11314}];
export const contents: Record<string, string> = {
  "isomerdesign": `# Bromantane
*Source: https://isomerdesign.com/PiHKAL/explore.php?id=744*

## Chemical Data

**IUPAC Name:** N-(4-Bromophenyl)adamantan-2-amine

**Molecular Formula:** C16H20B

**Molecular Weight:** 306.241

**SMILES:** \`Brc1ccc(cc1)NC1C2CC3CC1CC(C2)C3\`

**InChI:** \`InChI=1S/C16H20BrN/c17-14-1-3-15(4-2-14)18-16-12-6-10-5-11(8-12)9-13(16)7-10/h1-4,10-13,16,18H,5-9H2\`

## External References

- [](https://en.wikipedia.org/wiki/Markush_structure)
- [3849628](https://www.chemspider.com/Chemical-Structure.3849628.html/)
- [4660557](https://pubchem.ncbi.nlm.nih.gov/compound/4660557)
- [Q385533](https://www.wikidata.org/wiki/Q385533)
- [Bromantane](https://en.wikipedia.org/wiki/Bromantane)
`,
  "protestkit": `{
  "url": "https://psychonautwiki.org/wiki/Bromantane",
  "experiencesUrl": "https://www.reddit.com/search/?q=Bromantane",
  "name": "Bromantane",
  "aliases": [
    "bromantan",
    "ladasten"
  ],
  "aliasesStr": "bromantan,ladasten",
  "summary": "An unusual stimulant and anxiolytic drug with dopamine and serotonin reuptake inhibition properties. Infamously used as a doping agent in the 1996 Olympics. There are some concerns it may exacerbate the underlying causes of Alzheimer's disease.",
  "reagents": null,
  "classes": {
    "chemical": [
      "Adamantanes"
    ],
    "psychoactive": [
      "Stimulants",
      "Nootropic"
    ]
  },
  "toxicity": null,
  "addictionPotential": null,
  "tolerance": null,
  "crossTolerances": null,
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Threshold",
          "value": "< 10 mg"
        },
        {
          "name": "Light",
          "value": "10 - 50 mg"
        },
        {
          "name": "Common",
          "value": "50 - 100 mg"
        },
        {
          "name": "Strong",
          "value": "100 - 200 mg"
        },
        {
          "name": "Heavy",
          "value": "200 mg +"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.5 - 1.0 hours"
        },
        {
          "name": "Peak",
          "value": "2.0 - 4.0 hours"
        },
        {
          "name": "Total",
          "value": "6.0 - 10.0 hours"
        }
      ],
      "bioavailability": "42%"
    }
  ],
  "interactions": null,
  "effects": "Motivation enhancement, Memory enhancement, Dehydration, Vasoconstriction, Thought acceleration, Analysis enhancement, Cognitive euphoria, Stimulation, Wakefulness, Increased blood pressure, Muscle relaxation, Anxiety suppression, Increased music appreciation, Teeth grinding, Focus intensification, Tactile intensification, Stamina intensification",
  "categorized_effects": {
    "Physical effects": [
      "vasoconstriction",
      "temporary erectile dysfunction",
      "increased heart rate",
      "increased blood pressure",
      "teeth grinding",
      "Dehydration",
      "Stimulation",
      "Muscle relaxation",
      "Stamina intensification"
    ],
    "Mental effects": [
      "Motivation enhancement",
      "Memory enhancement",
      "Thought acceleration",
      "Analysis enhancement",
      "Cognitive euphoria",
      "Wakefulness",
      "Anxiety suppression",
      "Increased music appreciation",
      "Focus intensification"
    ],
    "Sensory effects": [
      "Tactile intensification"
    ],
    "Uncategorized effects": []
  }
}`,
  "psychonautwiki": `# Bromantane
*Source: https://psychonautwiki.org/wiki/Bromantane*

## Dosage & Duration

### Oral

**Dosage:**
- Bioavailability: 42%[1]
- Threshold: < 10 mg
- Light: 10 - 50 mg
- Common: 50 - 100 mg
- Strong: 100 - 200 mg
- Heavy: 200 mg +

**Duration:**
- Total: 6 - 10 hours
- Onset: 30 - 60 minutes
- Peak: 2 - 4 hours

**Bromantane** (trade name **Ladasten / Ладастен** ) is a Russian pharmaceutical substance developed in the late 1980s that possesses both [stimulant](https://psychonautwiki.org/wiki/Stimulant) and [anxiolytic](https://psychonautwiki.org/wiki/Anxiety_suppression) properties. Although it is a commonly used medication in Russia and surrounding countries, it has not gained widespread recognition or pharmaceutical use in other countries. During the 1996 Olympic Games in Atlanta, 5 different Russian athletes tested positive for bromantane use.

A study conducted on human subjects displayed bromantane's ability to improve endurance and work capacity during stressful and intense conditions. This is because bromantane works as an actoprotector, a substance that makes the body more stable under physical duress without increasing oxygen consumption.

## Chemistry

Bromantane is a chemical derivative of [adamantane](https://psychonautwiki.org/wiki/Adamantane) , a polyhedral organic compound containing four fused cyclohexane rings. Bromantane's structure consists of adamantane bound at R 2 to a nitrogenous group which is in turn bonded to a phenyl ring substituted at R 4 with a bromine group.

## Pharmacology

Bromantane is atypical among [stimulants](https://psychonautwiki.org/wiki/Stimulant) in the sense that it inhibits [serotonin](https://psychonautwiki.org/wiki/Serotonin) reuptake in addition to inhibiting [dopamine](https://psychonautwiki.org/wiki/Dopamine) reuptake. It also increases levels of [norepinephrine](https://psychonautwiki.org/wiki/Noradrenaline) , but its means of doing so are unclear. Bromantane's [anxiolytic](https://psychonautwiki.org/wiki/Anxiety_suppression) properties are due to its strengthening of GABA-ergic mediation.

Unlike typical stimulants such as [amphetamine](https://psychonautwiki.org/wiki/Amphetamine) , bromantane's effects come primarily through the upregulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase (L-DOPA decarboxylase). Rodent studies have shown a 2-2.5x increase in these enzymes following administration of bromantane, and their upregulation causes a downstream increase in levels of dopamine, serotonin and epinephrine.

Although not relevant at clinical dosages, bromantane has been found to produce [anticholinergic](https://psychonautwiki.org/wiki/Deliriant) effects, including both antimuscarinic and antinicotinic actions, at very high doses in animals.

## Subjective effects

***Disclaimer:** The effects listed below cite the [Subjective Effect Index](https://psychonautwiki.org/wiki/Subjective_effect_index) ( **SEI** ), an open research literature based on anecdotal user reports and the personal analyses of [PsychonautWiki](https://psychonautwiki.org/wiki/PsychonautWiki) [contributors](https://psychonautwiki.org/wiki/Special:TopUsers) . As a result, they should be viewed with a healthy degree of skepticism.*

*It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. *Likewise, **adverse effects** become increasingly likely with higher doses and may include **addiction, severe injury, or death*** ☠.*
### Physical effects
 
- - **[Stimulation](https://psychonautwiki.org/wiki/Stimulation)** - It is generally not described as forced and is mild comparing to that produced by typical stimulants like amphetamine.
- **[Stamina enhancement](https://psychonautwiki.org/wiki/Stamina_enhancement)**
- **[Dehydration](https://psychonautwiki.org/wiki/Dehydration)** [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Vasoconstriction](https://psychonautwiki.org/wiki/Vasoconstriction)** [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Increased blood pressure](https://psychonautwiki.org/wiki/Increased_blood_pressure)** [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Muscle relaxation](https://psychonautwiki.org/wiki/Muscle_relaxation)** [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Tactile enhancement](https://psychonautwiki.org/wiki/Tactile_enhancement)** - Bromantane can cause warm pleasurable skin feeling simillar to that produced by empathogens like MDMA but the effect is far less pronounced. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Teeth grinding](https://psychonautwiki.org/wiki/Teeth_grinding)** - Although bromantane has muscle relaxing properties it can cause jaw clenching especially when mixed with caffeine. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*] ### Cognitive effects
 
- - **[Anxiety suppression](https://psychonautwiki.org/wiki/Anxiety_suppression)** - Bromantane produces anxiety supression which is unusual comparing to typical stimulants like amphetamine which can actually cause feelings of anxiety.
- **[Focus enhancement](https://psychonautwiki.org/wiki/Focus_enhancement)**
- **[Thought acceleration](https://psychonautwiki.org/wiki/Thought_acceleration)**
- **[Analysis enhancement](https://psychonautwiki.org/wiki/Analysis_enhancement)**
- **[Memory enhancement](https://psychonautwiki.org/wiki/Memory_enhancement)**
- **[Motivation enhancement](https://psychonautwiki.org/wiki/Motivation_enhancement)**
- **[Cognitive euphoria](https://psychonautwiki.org/wiki/Cognitive_euphoria)**
- **[Wakefulness](https://psychonautwiki.org/wiki/Wakefulness)**
- **[Increased music appreciation](https://psychonautwiki.org/wiki/Increased_music_appreciation)** - It appears less consistently and the effect is less pronounced comparing to typical stimulants like amphetamine.
## Toxicity and harm potential

### Lethal dosage

The LD 50 of bromantane in mice has been established at 8100 mg/kg.

It is strongly recommended that one use [harm reduction practices](https://psychonautwiki.org/wiki/Responsible_drug_use) when using this substance.

### Tolerance and addiction potential

Unlike other [stimulants](https://psychonautwiki.org/wiki/Stimulant) , bromantane does not seem to produce tolerance, addiction, or withdrawal symptoms upon discontinuation. Due to its irregular mechanism of action, it does not exhibit cross-tolerance with other typical stimulants, and anecdotal reports have claimed it can be used to reduce stimulant tolerance, which is caused in part by downregulation of tyrosine hydroxylase which bromantane can increase.

#### Long term effects

Bromantane has been shown to uniquely cause long-term changes to gene expression involved in dopamine metabolism in rats. It is unclear if this effect is relevant to humans.

There are multiple anecdotal reports of long-term increases in energy levels, likely from elevated dopamine, from use of bromantane for periods of several months. These effects are claimed to persist even after stopping use of the drug, although have been noted to diminish over time, on a scale of weeks to a month. In a study investigating bromantane in the treatment of neurasthenia, a persistent reduction in fatigue was noted for a month following withdrawal of the drug.

### Dangerous Interractions

Due to its mechanism of action, bromantane can cause an unexpectedly strong reaction when mixed with other stimulants such as [amphetamine](https://psychonautwiki.org/wiki/Amphetamine) , [cocaine](https://psychonautwiki.org/wiki/Cocaine) and/or [methylphenidate](https://psychonautwiki.org/wiki/Methylphenidate) . It is advised to avoid the use of stimulants with bromantane due to the potential for much stronger reactions than one would expect.

## Legal status

- **Germany** : Bromantane is not a controlled substance under the BtMG ( *Narcotics Act* ) or the NpSG ( *New Psychoactive Substances Act* ). According to §2 AMG ( *Medicines Act* ) it would fall under the definition of a medicine because it induces pharmacological effect. By a decision of the European Court of Justice, this definition was declared ineffective because it was not compatible with EU law. Bromantane can be considered legal.
- **Russia** : In Russia Bromantane has been discontinued in 2017 and will not be available in the nearest future. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **Switzerland** : Bromantane is not controlled under Buchstabe A, B, C and D. It could be considered legal.
- **United States** : Bromantane is uncontrolled in the United States and has not been approved by the FDA for human use. However, this has led [nootropic](https://psychonautwiki.org/wiki/Nootropic) vendor websites to sell bromantane under the label of "not for human consumption." [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]

## See also

- [Responsible use](https://psychonautwiki.org/wiki/Responsible_use)
- [Tianeptine](https://psychonautwiki.org/wiki/Tianeptine)
- [Memantine](https://psychonautwiki.org/wiki/Memantine)
- [Noopept](https://psychonautwiki.org/wiki/Noopept)
- [Nootropics](https://psychonautwiki.org/wiki/Nootropics)

## External links

- [Bromantane (Wikipedia)](https://en.wikipedia.org/wiki/Bromantane)
- [Bromantane (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=744)

## Literature

- Reichlin, S. (1969). Handbook of Experimental Pharmacology. The American Journal of The Medical Sciences (Vol. 258). [https://doi.org/10.1097/00000441-196911000-00008](https://doi.org/10.1097/00000441-196911000-00008)
- Krapivin, S. V, Sergeeva, S. A., & Morozov, I. S. (1993). [A quantitative pharmaco-electroencephalographic analysis of the action of bromantane]. Biulleten’ Eksperimental’noi Biologii I Meditsiny, 116(11), 515–8. Retrieved from [http://www.ncbi.nlm.nih.gov/pubmed/8312546](http://www.ncbi.nlm.nih.gov/pubmed/8312546)
- Burnat, P., Payen, A., Brumant-Payen, C. Le, Hugon, M., & Ceppa, F. (1997). Bromontan, a new doping agent. The Lancet, 350(9082), 963–964. [https://doi.org/10.1016/S0140-6736(05)63310-7](https://doi.org/10.1016/S0140-6736(05)63310-7)
- Viatleva, O. A., Barchukov, V. G., Morozov, I. S., Salenko, I. A., & Zhirnov, E. N. (2000). [The neuro- and psychophysiological effects of bromantane]. Voenno-Meditsinskii Zhurnal, 321(8), 61–5, 96. Retrieved from [http://www.ncbi.nlm.nih.gov/pubmed/10998997](http://www.ncbi.nlm.nih.gov/pubmed/10998997)
- Iezhitsa, I. N., Spasov, A. A., & Bugaeva, L. I. (2001). Effects of bromantan on offspring maturation and development of reflexes. Neurotoxicology and Teratology, 23(2), 213–222. [https://doi.org/10.1016/S0892-0362(01)00119-2](https://doi.org/10.1016/S0892-0362(01)00119-2)
- Iezhitsa, I. N., Spasov, A. A., Bugaeva, L. I., & Morozov, I. S. (2002). Toxic effect of single treatment with bromantane on neurological status of experimental animals. Bulletin of Experimental Biology and Medicine, 133(4), 380–383. [https://doi.org/10.1023/A:1016206306875](https://doi.org/10.1023/A:1016206306875)
- Oliynyk, S., & Oh, S. (2012). The pharmacology of actoprotectors: Practical application for improvement of mental and physical performance. Biomolecules and Therapeutics, 20(5), 446–456. [https://doi.org/10.4062/biomolther.2012.20.5.446](https://doi.org/10.4062/biomolther.2012.20.5.446)
- Morozov, I. S., Klimova, N. V, Karpova, T. D., & Shestopalov, S. S. (n.d.). [The characteristics of the neuropsychotropic activity of bromantane in laboratory animals]. Eksperimental’naia I Klinicheskaia Farmakologiia, 62(2), 3–6. Retrieved from [http://www.ncbi.nlm.nih.gov/pubmed/10340117](http://www.ncbi.nlm.nih.gov/pubmed/10340117)
- Kudrin, V. S., Sergeeva, S. A., Krasnykh, L. M., Miroshnichenko, I. I., Grekhova, T. V, & Gaĭnetdinov, R. R. (n.d.). [The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain]. Eksperimental’naia I Klinicheskaia Farmakologiia, 58(4), 8–11. Retrieved from [http://www.ncbi.nlm.nih.gov/pubmed/7580761](http://www.ncbi.nlm.nih.gov/pubmed/7580761)

## References
1. ↑ Oliynyk, S., Oh, S. (September 2012).["The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762282/).*Biomolecules & Therapeutics*.**20**(5): 446–456.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.4062/biomolther.2012.20.5.446](//doi.org/10.4062%2Fbiomolther.2012.20.5.446).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1976-9148](//www.worldcat.org/issn/1976-9148).
2. ↑ Krapivin, S. V., Sergeeva, S. A., Morozov, I. S. (November 1993). "[A quantitative pharmaco-electroencephalographic analysis of the action of bromantane]".*Biulleten’ Eksperimental’noi Biologii I Meditsiny*.**116**(11): 515–518.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0365-9615](//www.worldcat.org/issn/0365-9615).
3. ↑ Burnat, P., Payen, A., Brumant-Payen, C. L., Hugon, M., Ceppa, F. (September 1997).["Bromontan, a new doping agent"](https://linkinghub.elsevier.com/retrieve/pii/S0140673605633107).*The Lancet*.**350**(9082): 963–964.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/S0140-6736(05)63310-7](//doi.org/10.1016%2FS0140-6736%2805%2963310-7).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0140-6736](//www.worldcat.org/issn/0140-6736).
4. ↑ Viatleva, O. A., Barchukov, V. G., Morozov, I. S., Salenko, I. A., Zhirnov, E. N. (August 2000). "[The neuro- and psychophysiological effects of bromantane]".*Voenno-Meditsinskii Zhurnal*.**321**(8): 61–65, 96.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0026-9050](//www.worldcat.org/issn/0026-9050).
5. ↑ 5.0 5.1 Oliynyk, S., Oh, S.-K. (30 September 2012).["The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance"](http://koreascience.or.kr/journal/view.jsp?kj=OOOMB4&py=2012&vnc=v20n5&sp=446).*Biomolecules and Therapeutics*.**20**(5): 446–456.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.4062/biomolther.2012.20.5.446](//doi.org/10.4062%2Fbiomolther.2012.20.5.446).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1976-9148](//www.worldcat.org/issn/1976-9148).
6. ↑ Kudrin, V. S., Sergeeva, S. A., Krasnykh, L. M., Miroshnichenko, I. I., Grekhova, T. V., Gaĭnetdinov, R. R. (August 1995). "[The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain]".*Eksperimental’naia I Klinicheskaia Farmakologiia*.**58**(4): 8–11.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0869-2092](//www.worldcat.org/issn/0869-2092).
7. ↑ Mikhaylova, M; Vakhitova, J; Yamidanov, R; Salimgareeva, M; Seredenin, S; Behnisch, T (2007). "The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats". Neuropharmacology. 53 (5): 601–608. https://doi.org/10.1016%2Fj.neuropharm.2007.07.001
8. ↑ Morozov, I. S., Pukhova, G. S., Avdulov, N. A., Sergeeva, S. A., Spasov, A. A., Iezhitsa, I. N. (February 1999). "[The mechanisms of the neurotropic action of bromantan]".*Eksperimental’naia I Klinicheskaia Farmakologiia*.**62**(1): 11–14.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0869-2092](//www.worldcat.org/issn/0869-2092).
9. ↑ Iezhitsa, I. N., Spasov, A. A., Bugaeva, L. I., Morozov, I. S. (April 2002). "Toxic effect of single treatment with bromantane on neurological status of experimental animals".*Bulletin of Experimental Biology and Medicine*.**133**(4): 380–383.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1023/a:1016206306875](//doi.org/10.1023%2Fa%3A1016206306875).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0007-4888](//www.worldcat.org/issn/0007-4888).
10. ↑ Morozov, I. S., Klimova, N. V., Karpova, T. D., Shestopalov, S. S. (April 1999). "[The characteristics of the neuropsychotropic activity of bromantane in laboratory animals]".*Eksperimental’naia I Klinicheskaia Farmakologiia*.**62**(2): 3–6.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0869-2092](//www.worldcat.org/issn/0869-2092).
11. ↑ Iëzhitsa IN, Bugaeva LI, Spasov AA, Morozov IS (2000).["[Effect of bromantane on the rat neurologic status in two month course]"](https://pubmed.ncbi.nlm.nih.gov/11109517/).*Eksp Klin Farmakol*(in Russian).**63**(5): 13–7.[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[11109517](//www.ncbi.nlm.nih.gov/pubmed/11109517).
12. ↑ Vakhitova, I. V., Iamidanov, R. S., Vakhitov, V. A., Seredenin, S. B. (April 2005). "[DNA macroarray analysis of gene expression changes in rat brain after single administration of 2-aminoadamantane compound]".*Molekuliarnaia Biologiia*.**39**(2): 276–285.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0026-8984](//www.worldcat.org/issn/0026-8984).
13. ↑ [https://pubmed.ncbi.nlm.nih.gov/21322821/](https://pubmed.ncbi.nlm.nih.gov/21322821/)
14. ↑ ["Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG)"](https://www.gesetze-im-internet.de/btmg_1981/BJNR106810981.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 28, 2019.
15. ↑ ["Neue-psychoaktive-Stoffe-Gesetz (NpSG)"](https://www.gesetze-im-internet.de/npsg/BJNR261510016.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 28, 2019.
16. ↑ ["§ 2 AMG"](https://www.gesetze-im-internet.de/amg_1976/__2.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 28, 2019.
17. ↑ Prof. Dr. Helmut Pollähne (July 11, 2014).["Cannabinoide Kräutermischungen vor dem EuGH: Legal Highs bleiben legal"](https://www.lto.de/recht/hintergruende/h/eugh-urteil-c35813-c18114-legal-highs-kein-arzneimittel-strafbar-amg-btmg/)[Cannabinoid herbal mixtures at the ECJ: Legal highs stay legal] (in German). LTO. Retrieved December 28, 2019.
18. ↑ ["Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html)(in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.NewPP limit report Cached time: 20251218075221 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.028 seconds CPU time usage: 0.306 seconds Real time usage: 0.660 seconds Preprocessor visited node count: 1564/1000000 Post‐expand include size: 100399/2097152 bytes Template argument size: 11508/2097152 bytes Highest expansion depth: 22/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 22541/5000000 bytes Lua time usage: 0.290/7 seconds Lua virtual size: 8.52 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 11Transclusion expansion time report (%,ms,calls,template) 100.00% 558.233 1 -total 51.71% 288.670 11 Template:Cite_journal 19.53% 109.018 1 Template:Effects/base 19.13% 106.799 1 Template:Effect_list 18.69% 104.353 2 Template:Effect_column 17.68% 98.715 1 Template:Effects/physical 17.31% 96.643 2 Template:Effect_panel 16.81% 93.862 8 Template:Citation_needed 10.88% 60.721 1 Template:SubstanceBox/Bromantane 10.33% 57.690 1 Template:SubstanceBox`,
  "tripsit-factsheets": `# Bromantane
*Source: https://tripbot.tripsit.me/api/tripsit/getDrug/bromantane*

## Classification
- **Categories:** depressant, stimulant, research-chemical, nootropic

## Dosage

### Oral
- **Common:** 100-200mg
- **Light:** 50-100mg
- **Strong:** 200-400mg+

## Duration
- **Onset:** {'_unit': 'minutes', 'Oral': '10-30'}
- **Duration:** 4-8 hours
- **After Effects:** 1-10 hours
`,
  "wikipedia": `# Bromantane
*Source: https://en.wikipedia.org/wiki/Bromantane*

Bromantane, sold under the brand name Ladasten, is an atypical central nervous system (CNS) stimulant and anxiolytic drug of the adamantane family that is related to amantadine and memantine. Medically, it is approved in Russia for the treatment of neurasthenia. Although the effects of bromantane have been determined to be dependent on the dopaminergic and possibly serotonergic neurotransmitter systems, its exact mechanism of action is unknown, and is distinct in its properties relative to typical stimulants such as amphetamine. Bromantane has sometimes been described as an actoprotector (synthetic adaptogen).

## Effects

### Clinical research

The therapeutic effects of bromantane in asthenia are said to onset within 1–3 days. It has been proposed that the combination of stimulant and anxiolytic activity may give bromantane special efficacy in the treatment of asthenia.
In a large-scale, multi-center clinical trial of 728 patients diagnosed with asthenia in Russia, bromantane was given for 28 days at a daily dose of 50 mg or 100 mg. The study concluded with an impression score of 76.0% on the CGI-S and 90.8% on the CGI-I for bromantane, indicating that it is broadly applicable and highly effective. The therapeutic benefit against asthenia was observed to still be present one month after discontinuation of the drug. 3% of patients experienced side effects; though none were considered serious; and 0.8% of patients discontinued treatment due to side effects. Bromantane was also noted to normalize the sleep-wake cycle.

### Psychotropic effects

Bromantane is described primarily as a mild stimulant and anxiolytic. It is also said to possess anti-asthenic properties. Bromantane is reported to improve physical and mental performance, hence it could be considered a performance-enhancing drug.
Bromantane has been found to lower the levels of pro-inflammatory cytokines IL-6, IL-17 and IL-4 and to normalize behavior in animal models of depression, and may possess clinical efficacy as an antidepressant. It has also been found to increase sexual receptivity and proceptivity in rats of both sexes, which was attributed to its dopaminergic actions. It has been proposed that bromantane may suppress prolactin levels by virtue of its dopaminergic properties as well. Bromantane has been found to "agonize" amphetamine-induced stereotypies in vivo, suggesting that it might potentiate certain effects of other stimulants.
The stimulant effects of bromantane onset gradually within 1.5–2 hours and last for 8–12 hours when taken orally.

## Pharmacology

### Pharmacodynamics

#### Dopamine synthesis enhancement

Although it is frequently labeled as a stimulant, bromantane is distinct in its pharmacology and effects relative to typical stimulants, such as the phenethylamines (e.g., amphetamine and its derivatives) and their structural analogues (e.g., methylphenidate, cocaine, mesocarb, etc.). Whereas the latter directly act on the dopamine transporter (DAT) to inhibit the reuptake and/or induce the release of dopamine, bromantane instead acts via indirect genomic mechanisms to produce a rapid, pronounced, and long-lasting upregulation in a variety of brain regions of the expression of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AAAD) (also known as DOPA decarboxylase), key enzymes in the dopamine biosynthesis pathway. For instance, a single dose of bromantane produces a 2–2.5 fold increase in TH expression in the rat hypothalamus 1.5–2 hours post-administration. The biosynthesis and release of dopamine subsequently increase in close correlation with TH and AAAD upregulation. Enhancement of dopaminergic neurotransmission is observed in the hypothalamus, striatum, ventral tegmental area, nucleus accumbens, and other regions. As such, the key mechanism of the pharmacological activity and psychostimulant effects of bromantane is activation of the de novo synthesis of dopamine via modulation of gene expression. 
A selection of quoted excerpts from the medical literature detail the differences between bromantane and typical stimulants:

"Bromantane [does] not concede well-known psychostimulant of phenylalkylamine structure and its analogs (amphetamine, [mesocarb], [methylphenidate], etc.) by specific activity. In contrast, bromantane has neither addictive potential nor reveals redundant and exhausting activation of sympaticoadrenergic system, or decelerates the restoring of work capacity at preventive application before forthcoming activity in complicated conditions (hypoxia, high environmental temperature, physical overfatigue, emotional stress, etc.). Bromantane has no prohypoxic activity."
"The use of the drug, in contrast to the action of a typical psychostimulant, is not associated with the phenomenon of hyperstimulation and causes no consequences such as functional exhaustion of the body."
"Bromantane administration in therapeutic doses is characterized by the almost full absence of side effects including manifestations of withdrawal syndrome and hyperstimulation."
"[Bromantane] has low peripheral sympathomimetic effects. Moreover, no signs of [bromantane] dependence and withdrawal symptoms were found."
Bromantane is well tolerated and elicits few side effects (including peripheral sympathomimetic effects and hyperstimulation), does not appear to produce tolerance or dependence, has not been associated with withdrawal symptoms upon discontinuation, and displays an absence of addiction potential, contrary to typical stimulants. In accordance with human findings, animals exposed to bromantane for extended periods of time do not appear to develop tolerance or dependence.
The precise direct molecular mechanism of action by which bromantane ultimately acts as a dopamine synthesis enhancer is unknown. However, it has been determined that activation of certain cAMP-, Ca2+-, and phospholipid-dependent protein kinases such as protein kinase A and especially protein kinase C corresponds with the manifestation of the pharmacological effects of bromantane. Bromantane may activate intracellular signaling cascades by some mechanism (e.g., agonizing some as-yet-undetermined receptor) to in turn activate protein kinases, which in turn cause increased transcription of TH and AAAD.
The related drugs amantadine and memantine also have many properties similar to those of bromantane.
Researchers discovered that amantadine and memantine bind to and act as agonists of the σ1 receptor (Ki = 7.44 μM and 2.60 μM, respectively) and that activation of the σ1 receptor is involved in the central dopaminergic effects of amantadine at therapeutically relevant concentrations; the authors of the study stated that this could also be the mechanism of action of bromantane, as it is in the same family of structurally related compounds and evidence suggests a role of dopamine in its effects. But this could also be seen as evidence of the contrary since bromantane has effects that are distinctly different from amantadine and memantine.

#### Monoamine reuptake inhibition

Bromantane was once thought to act as a reuptake inhibitor of serotonin and dopamine. While bromantane can inhibit the reuptake of serotonin, dopamine, and to a lesser extent norepinephrine in vitro in rat brain tissue, the concentrations required to do so are extremely high (50–500 μM) and likely not clinically relevant. Although one study found an IC50 for dopamine transport of 3.56 μM, relative to 28.66 nM for mesocarb; neither drug affected serotonin transport at the tested concentrations, in contrast. The lack of typical stimulant-like effects and adverse effects seen with bromantane may help corroborate the notion that it is not acting significantly as a monoamine reuptake inhibitor, but rather via a different mechanism.

#### Other actions

Bromantane has been found to increase the expression of neurotrophins including brain-derived neurotrophic factor and nerve growth factor in certain rat brain areas.
Although not relevant at clinical dosages, bromantane has been found to produce anticholinergic effects, including both antimuscarinic and antinicotinic actions, at very high doses in animals, and these effects are responsible for its toxicity (that is, LD50) in animals.

### Pharmacokinetics

Bromantane is used clinically in doses of 50 mg to 100 mg per day in the treatment of asthenia. 
The rate of absorption in women is greater than in men, with maximum blood concentrations being reached at 2.75 and 4 hours after oral administration, respectively. 
The main metabolite of bromantane is 6β-hydroxybromantane.

## Chemistry

Bromantane is an adamantane derivative. It is also known as adamantylbromphenylamine, from which its name was derived.
Closely related adamantanes with similar effects include adapromine, amantadine, chlodantane, gludantane (gludantan), memantine, and rimantadine.

### Synthesis

The Leuckart reaction between adamantanone and 4-bromoaniline in the presence of formic acid produces bromantane.

## History

In the 1960s, the adamantane derivative amantadine (1-aminoadamantane) was developed as an antiviral drug for the treatment of influenza. Other adamantane antivirals subsequently followed, such as rimantadine (1-(1-aminoethyl)adamantane) and adapromine (1-(1-aminopropyl)adamantane). It was serendipitously discovered in 1969 that amantadine possesses central dopaminergic stimulant-like properties, and subsequent investigation revealed that rimantadine and adapromine also possess such properties. Amantadine was then developed and introduced for the treatment of Parkinson's disease due to its ability to increase dopamine levels in the brain. It has also notably since been used to help alleviate fatigue in multiple sclerosis.
With the knowledge of the dopaminergic stimulant effects of the adamantane derivatives, bromantane, which is 2-(4-bromophenylamino) adamantane, was developed in the 1980s at the Zakusov State Institute of Pharmacology, USSR Academy of Medical Sciences (now the Russian Academy of Medical Sciences) in Moscow as "a drug having psychoactivating and adaptogen properties under complicated conditions (hypoxia, high environmental temperature, physical overfatigue, emotional stress, etc.)". It was found to produce more marked and prolonged stimulant effects than the other adamantanes, and eventually entered use. The drug was notably given to soldiers in the Soviet and Russian militaries to "shorten recovery times after strong physical exertion". After the break-up of the Soviet Union in 1991, bromantane continued to be researched and characterized but was mainly limited in use to sports medicine (for instance, to enhance athletic performance). In 1996, it was encountered as a doping agent in the 1996 Summer Olympics when several Russian athletes tested positive for it, and was subsequently placed on the World Anti-Doping Agency banned list in 1997 as a stimulant and masking agent.
Bromantane was eventually repurposed in 2005 as a treatment for neurasthenia. It demonstrated effectiveness and safety for the treatment of the condition in extensive, large-scale clinical trials, and was approved for this indication in Russia under the brand name Ladasten sometime around 2009.
`,
};
